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Abstract
Background: Bothropstoxin-I (BthTx-I) is a Lys49-phospholipase A2 (Lys49-PLA2) from the venom of Bothrops jararacussu,
which despite of the lack of catalytic activity induces myotoxicity, inflammation and pain. The C-terminal region of the
Lys49-PLA2s is important for these effects; however, the amino acid residues that determine hyperalgesia and edema are
unknown. The aim of this study was to characterize the structural determinants for the Lys49-PLA2-induced nociception
and inflammation.
Methods: Scanning alanine mutagenesis in the active-site and C-terminal regions of BthTx-I has been used to study the
structural determinants of toxin activities. The R118A mutant was employed as this substitution decreases PLA2
myotoxicity. In addition, K115A and K116A mutants – which contribute to decrease cytotoxicity – and the K122A
mutant – which decreases both myotoxicity and cytotoxicity – were also used. The H48Q mutant – which does
not interfere with membrane damage or myotoxic activity – was used to evaluate if the PLA2 catalytic site is relevant
for the non-catalytic PLA2-induced pain and inflammation. Wistar male rats received intraplantar injections with mutant
PLA2. Subsequently, hyperalgesia and edema were evaluated by the paw pressure test and by a plethysmometer.
Native and recombinant BthTx-I were used as controls.
Results: Native and recombinant BthTx-I induced hyperalgesia and edema, which peaked at 2 h. The R118A mutant
did not induce nociception or edema. The mutations K115A and K116A abolished hyperalgesia without
interfering with edema. Finally, the K122A mutant did not induce hyperalgesia and presented a decreased
inflammatory response.
Conclusions: The results obtained with the BthTx-I mutants suggest, for the first time, that there are distinct residues
responsible for the hyperalgesia and edema induced by BthTx-I. In addition, we also showed that cytolytic activity is
essential for the hyperalgesic effect but not for edematogenic activity, corroborating previous data showing that
edema and hyperalgesia can occur in a non-dependent manner. Understanding the structure-activity relationship
in BthTx-I has opened new possibilities to discover the target for PLA2-induced pain.
Keywords: Lys49-Phospholipase A2, Hyperalgesia, Site-directed mutagenesis, Myotoxic effect, Edema,
Membrane damage
Background
Phospholipases A2 (PLA2; EC 3.1.1.4) are enzymes that
hydrolyze the sn-2 acyl bond of glycerophospholipids,
releasing free fatty acids and lysophospholipids [1].
Secretory PLA2s are found in a wide variety of biological
fluids such as inflammatory exudates, and the venoms of
arthropods, mollusks and snakes [2]. These enzymes are
abundant in Bothrops snake venoms and display
pharmacological activities characterized by myotoxic,
neurotoxic, anticoagulant, hypotensive, hemolytic, plate-
let aggregation inhibition, bactericidal, pro-inflammatory
and nociceptive effects [2–4]. A subfamily of class IIA
PLA2s has been purified from the venoms of several
viperid snakes, in which the Asp49 residue is replaced
by Lys [5, 6]. These Ly49-PLA2s conserve the basic
structural fold of this family of enzymes but lack
catalytic activity.
While the Lys49-PLA2s do not show catalytic activity,
in vitro studies showed they are able to disrupt liposome
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membranes and release their contents by a Ca2+-inde-
pendent mechanism that does not involve hydrolysis of
membrane phospholipids [7]. Despite the lack of catalytic
activity, the in vivo activities of the Lys49-PLA2s include
myonecrosis, bactericidal activity, local inflammation and
pain [6, 8–13]. Chacur et al. [11] have demonstrated
that the C-terminal cationic/hydrophobic sequence cor-
responding to amino acids 115–129 of a Lys49-PLA2
isolated from Bothrops asper is critical for the sensation
of pain. This finding is supported by the demonstration
that heparin partially neutralizes hyperalgesia induced
by this toxin, and the direct induction of hyperalgesia
by the peptide corresponding to amino acids 115–129,
although having lower activity than the native toxin.
Despite this evidence, the amino acids responsible for
this effect are unknown.
Scanning alanine mutagenesis is a useful strategy to
study the structural determinants of the activities of
Lys49-PLA2. In this regard, Chioato et al. [14] have dem-
onstrated that amino acid residues in C-terminal region of
a Lys49-PLA2 from the venom of Bothrops jararacussu
(BthTx-I) determine its biological activity. It has been
demonstrated that the Lys122Ala mutant does not display
myotoxic activity while Arg115Ala and Arg116Ala mutants
do not display membrane-damaging activities. Moreover,
His48Gln substitution, which eliminates any possible
catalytic activity, does not influence the biological or
membrane damaging proprieties of BthTx-I. Using these
well-characterized functional point mutants in the active-
site and C-terminal regions of the BthTx-I, we aimed to
characterize the structural determinants for the Lys49-
PLA2-induced nociception and inflammation, and more
specifically, the edematogenic response.
Methods
Protein purification from crude venom
Bothropstoxin-I (BthTx-I) was purified from crude lyophi-
lized Bothrops jararacussu venom using a single step
cation-exchange chromatography as previously described
[15]. The BthTx-I was eluted as a single peak and then
dialyzed against 5 mM Tris–HCl, pH 7.5, for 36 h with
buffer changes every 12 h and concentrated 10-fold by
lyophilization. Protein purity was evaluated by silver
staining of SDS-PAGE gels [16].
Site directed mutagenesis
A full-length cDNA encoding BthTx-I has been previously
isolated from B. jararacussu venom gland cDNA by RT-
PCR (GenBank Acc. No. X78599) [17], and subcloned into
the expression vector pET3-d [18]. The nucleotide se-
quencing has confirmed the construct in which Ser1 of
the BthTx-I is preceded by a Met, and a stop codon imme-
diately follows Cys133. After linearization of this construct
with ScaI, site directed mutagenesis of the BthTx-I was
performed by PCR mutagenesis [19] to introduce single
mutations: Lys115→Ala (K115A), Lys116→Ala (K116A),
Arg118→Ala (R118A), Lys122→Ala (K122A) and His48→
Gln (H48Q). The final PCR reactions were performed
using oligonucleotides complementary to the vector se-
quences flanking the BthTx-I insert which contained
restriction sites for XbaI (5′-extremity) and BamHI
(3′-extremity). After digestion with these enzymes, the
amplified fragments were subcloned into the equivalent
sites in the expression vector pET3d and fully sequenced.
Recombinant protein expression and purification
A 150-mL volume of growth medium (2.5 g yeast extract;
10 mM MgSO4; 15 μg/L chloramphenicol; 150 μg/L
ampicillin; pH 7.5) was inoculated with Escherichia coli
strain BL21(DE3)pLysS transformed with the native or
mutant constructs in pET3d, and grown at 37 °C to an
A600 of 0.6. Recombinant protein expression was induced
by addition of 0.6 mM isopropylthiogalactoside, and the
culture was grown for an additional period of 5 h. Inclu-
sion bodies were isolated from bacterial pellets by re-
peated rounds of sonication in 20 mL of lysis buffer (50
mM Tris–HCl, pH 8.0; 1 mM EDTA; 0.4 M urea; 1% Tri-
ton X-100) followed by centrifugation at 12,000 g. The
protocol for the solubilization and refolding of recombin-
ant BthTx-I in the presence of a gel filtration medium was
performed as previously described [18]. The refolded pro-
tein was applied directly to the cation exchange column
and eluted as described earlier for the purification of the
native BthTx-I from crude venom.
Animals
Male Wistar rats, weighing between 170 and 190g were
used. Rats were housed in a temperature-controlled (21 ±
2 °C) and light-controlled (12/12 h light/dark cycle) room
with standard rodent rations and water ad libitum. All
procedures were conducted in accordance with the guide-
lines of the International Association for the Study of Pain
[20] and were approved by the Institutional Animal Care
Committee of the Butantan Institute (CEUAIB, protocol
number 118/2002).
Pharmacological treatments
For the evaluation of hyperalgesia and allodynia, animals
were injected with either 0.1 mL of sterile phosphate-
buffered saline (PBS) solution (control animals) or 0.1 mL
PBS containing the appropriate concentration of native,
recombinant or mutant BthTx-I into the subplantar sur-
face of one hind paw. For evaluation of edema, whereas
toxins were injected into a hind paw and the PBS was
administered in the contralateral paw.
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Evaluation of mechanical hyperalgesia (Randall and
Selitto test)
An Ugo-Basile pressure apparatus [21] was used to assess
pressure pain thresholds prior to, and again at different
times after, intraplantar injection of native, recombinant,
mutant BthTx-I or vehicle into the right hind paw. The
contralateral paw was not injected. Testing was blind with
respect to group designation. Briefly, a force (in g) with in-
creasing magnitude was applied to the paw. The force
needed to induce paw withdrawal was recorded as the
pain threshold. To reduce stress, the rats were exposed to
the testing procedure the day before the experiment, as
previously described [22].
Evaluation of low threshold mechanical allodynia (von
Frey)
The von Frey test [23] was used to assess low-threshold
mechanical pain thresholds prior to intraplantar injection
of the toxins or PBS (control) at different periods of time
later on. This test was performed as previously described
in detail, using the modified up-down method [24]. Briefly,
a logarithmic series of ten calibrated Semmes-Weinstein
monofilaments (von Frey hairs, Stoelting, Wood Dale,
USA) was applied to the right hind paw to determine the
stimulus intensity threshold stiffness required to elicit a
paw withdrawal response.
Log stiffness of the hairs is determined by log10 (milli-
grams × 10) and ranged from 3.61 (407 mg) to 5.18
(15.136 mg). Basal line assessment was initiated with the
2.041 mg hair. In the event of a paw withdrawal, the
same hair was again presented 30–60 s later. If the re-
sponse was again elicited, the 407 mg monofilament was
presented. In the absence of a paw withdrawal response
to the 407 mg stimulus, the next stronger monofilament
was presented (692 mg). The monofilament that elicited
a clear response was recorded, and was presented once
again 30–60 s later. If the animal withdrew its paw on
two consecutive trials with the same stiffness value, no
further von Frey hairs were tested.
However, in the absence of a response to the initial
2.041 mg monofilament, presentation of monofilaments
continued in ascending order until two consecutive re-
sponses were elicited from the same monofilament. All
single responses were recorded, but assessment was
complete only after two consecutive responses were elic-
ited from the same monofilament. In instances when
rats failed to respond, the strongest stimulus (15.136
mg) was considered to be the cut-off value.
Responses that occurred to the weakest stimulus (407
mg) were assigned the lower cut-off value for that time
point. To reduce stress, rats were habituated to the ex-
perimental environment on each of the four days before
experiments. Behavioral responses were used to calculate
the 50% paw withdrawal threshold (absolute threshold)
by fitting a Gaussian integral psychometric function
using a maximum-likelihood fitting method. This fitting
method allows parametric analyses [24, 25].
Evaluation of edema
The volume increase (edema) of paws up to the tibiotarsal
articulation was plethysmographically measured before
toxin or PBS (control) injection and subsequently at
chosen time intervals according to the method of Van
Arman et al. [26]. The percentage of increase in paw
volume was determined for each paw. The difference
between the values obtained for both paws was used as
a measure of edema.
Statistical analysis
The results are presented as the mean ± SEM. The statis-
tical evaluation of data was conducted using a two-way
analysis of variance (ANOVA) with post-hoc testing by
Tukey. A value of p < 0.05 was considered significant.
Results
Characterization of hyperalgesia and edema induced by
native and recombinant bothropstoxin-I
Intraplantar injection of 2.5 μg of native BthTx-I did not
alter the sensitivity to pressure pain, as measured by the
Randall and Sellito test. In contrast, doses of 5, 10 and
20 μg/paw decreased the pain threshold (28%, 43% and
42%, respectively) of the animals as compared to the
basal values. The peak of mechanical hyperalgesia was
detected at 2 h. Intraplantar PBS injection (vehicle con-
trol) did not modify the pain threshold of the animals
(Fig. 1a). Native BthTx-I also induced a significant ede-
matogenic response when injected at 10 and 20 μg/paw.
The dose of 10 μg/paw caused maximal response at 2 h
(44%), while a dose of 20 μg/paw showed a peak effect 1
h (47%) after toxin administration, decreasing thereafter
and completely disappearing within 24 h (Fig. 1b).
In order to evaluate whether the recombinant form of
BthTx-I induces hyperalgesia and edema, a dose response
curve was performed for recombinant BthTx-I. As is the
case for the native toxin, the intraplantar injection of 2.5
μg/paw of recombinant BthTx-I did not induce significant
alteration in the pain threshold of the animals. Doses of 5,
10 and 20 μg/paw significantly decreased the pain
threshold as compared with baseline, 2h after toxin in-
jection (27%, 42% and 41%, to 5, 10 and 20 μg/paw, re-
spectively). Injection of PBS (control) did not modify
the pain threshold of the animals (Fig. 1c). Moreover,
the doses of 5, 10 and 20 μg/paw caused a significant
edematogenic response. The peak of the edematogenic
response was detected 2 h after injection of 5 μg/paw
(34%) of BthTx-I, or 1 h after the administration of 10
(46%) or 20 μg/paw (50%) of the toxin. Intraplantar
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injection of PBS (vehicle control) did not alter the paw
volume of the animals (Fig. 1d).
For comparative analysis, native and recombinant
BthTx-I at 10 μg/paw induced similar intensity of hyper-
algesia (Fig. 1e). Although the recombinant BthTx-I did
not induce edema at the same magnitude as native at 1 h,
both toxins induced similar edema 2 h after the treatment
(Fig. 1f). Therefore, the dose of 10 μg/paw was selected
for subsequent studies.
Effect of BthTx-I site-directed mutagenesis on rat pain
threshold and paw volume
In order to investigate whether the residues involved in
the determination of myotoxic activities were also crit-
ical for hyperalgesia and edema, the BthTx-I mutant
R118A was tested. BthTx-I-induced hyperalgesia was
blocked by R118A mutation (in which the myotoxic
activity is reduced) (Fig. 2a). In addition, the R118A
mutation significantly decreased the edema induced by
recombinant BthTx-I (Fig. 2b).
In order to investigate whether the residues involved in
the BthTx-I membrane damaging activities were also crit-
ical for hyperalgesia and edema, the K115A and K116A
mutants were tested. BthTx-I induced hyperalgesia was
completely abolished by both K115A and K116A (which
reduce the membrane-damaging activity) (Fig 3a).
The K122A mutation, which significantly reduces
both myotoxic and membrane damaging activities also
reduced the rat hind paw hyperalgesia induced by
BthTx-I (Fig. 4a). The K122A mutation also signifi-
cantly decreased the edema induced by recombinant
BthTx-I (Fig. 4b).
The H48Q mutation eliminates catalytic activity in class
II PLA2s, and even though no catalytic activity is detected
in BthTx-I, this mutant was used as a control to eliminate
the possibility that the observed effects are the result of
phospholipid hydrolysis. The H48Q mutation did not
Fig. 1 Effect of native and recombinant bothropstoxin I injection on the pain threshold and paw volume. a Effect of the native-BthTx intraplantar
injection on the pain threshold and b on paw volume, at different doses. c Effect of recombinant BthTx-I intraplantar injection on the pain threshold
and d on paw volume, at different doses. e Comparison between native and recombinant BthTx-I hyperalgesic and f edematogenic effects. The pain
threshold of the animals was determined in rat hind paw before at different times after the intraplantar injection of PBS (control group) or
toxins. Sensitivity to pain was measured as the threshold response to pressure and expressed as g. The edema was determined by an increase
in the volume in the right hind paw of rats compared with the control contralateral paw. The paw volume was obtained pletsmografically.
Each point represents the mean ± SEM of six animals. *Significantly different from mean values before venom injection and #different from
BthTx-I-recombinant (BthTx-I rec) (p < 0.05)
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modify the hyperalgesia or edematogenic response in-
duced by BthTx-I (Fig. 5a and Fig 5b).
Characterization of allodynia induced by native and
recombinant bothropstoxin-I
Intraplantar injection (10 μg/paw) of either the native or
recombinant lowered withdrawal thresholds, as mea-
sured by the von Frey test. This effect was observed 2 h
after native Bthtx-I (65%) or recombinant BthTx-I (58%)
injection, and completely disappeared within 24 h. The
injection of PBS (control group) did not modify the pain
threshold of the animals (Fig. 6a).
Effect of BthTx-I site-directed mutagenesis on allodynia
The intraplantar administration of H48Q (10 μg/paw)
lowered withdrawal thresholds, comparing with the
baseline. The allodynic effect was observed 2 h after
toxin injection (58%). The other BthTx-I mutants
(Arg118→Ala, Arg115→Ala, Arg116→Ala, Arg122→
Ala) did not alter the threshold (Fig. 6b).
Discussion
Site-directed mutagenesis studies can identify the struc-
tural determinants for biological activities of venom
PLA2s. In this study, we demonstrate for the first time
the involvement of amino acids in the C-terminal region
in the nociceptive activity of the BthTx-I, a non-catalytic
Lys49-PLA2 from Bothrops jararacussu venom. In
addition, we have demonstrated that the same residues
that are determinants of myotoxicity of the BthTx-I are
also involved in hyperalgesia and inflammation, whereas
the residues responsible for the cytolytic activity only
contribute to the nociceptive effect of the protein.
In the experimental procedures, the recombinant
BthTx-I was used as control for all the behavior experi-
ments performed. Circular dichroism spectroscopic ana-
lysis has previously confirmed that the protein secondary
structures were preserved in the recombinant molecule,
as well as its biological activities (myotoxicity and cytolytic
effects). Here we have shown that the recombinant BthTx-
I displays hyperalgesic and edematogenic responses with
similar onset, intensity and time course to those observed
for the native BthTx-I. The edematogenic activity of the
Fig. 3 Effect of BthTx-I K115A and K116A (Lys115→ Ala and Lys116→ Ala) mutagenesis on rat pain threshold and paw volume. Decrease in
a threshold response and b paw volume were determined in rat hind paw before and 2, 4, 6 and 24 h after the intraplantar injection of PBS (control
group) or R115A, or R116A, or recombinant BthTx-I. Sensitivity to pain was measured as the threshold response to pressure and expressed as g. The
paw volume was obtained pletsmografically. Each point represents the mean ± SEM of six animals. *Significantly different from mean values before
venom injection (p < 0.05)
Fig. 2 Effect of BthTx-I R118A (Arg118→ Ala) mutagenesis on rat pain threshold and paw volume. Decrease in a threshold response and b paw
volume were determined in rat hind paw before and 2, 4, 6 and 24 h after the intraplantar injection of PBS (control group) or R118A, or recombinant
BthTx-I. The paw volume was obtained pletsmografically. Sensitivity to pain was measured as the threshold response to pressure and expressed as g.
The paw volume was obtained pletsmografically. Each point represents the mean ± SEM of six animals. *Significantly different from mean values before
venom injection and #different from BthTx-I-recombinant (BthTx-I rec) (p < 0.05)
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native BthTx-1 has been previously demonstrated [27, 28].
However, to the best of our knowledge, this is the first
report showing that BthTx-I induces hyperalgesia in an
experimental model of pain evaluation.
It is well established that the PLA2 component con-
tributes to the local effects induced by the Bothrops
snake envenomation. Our group has previously demon-
strated that both the Lys49-PLA2 that is devoid of cata-
lytic activity, and the catalytically active Asp49-PLA2
from Bothrops asper venom cause significant local
hyperalgesia in rat paws after intraplantar injection. The
hyperalgesic effect induced by these PLA2s is mediated
by biogenic amines, bradykinin, cytokines, prostaglan-
dins and sympathomimetic amines that may interact and
be sequentially released [11].
Because Lys49-PLA2s are unable to catalyze phospho-
lipid hydrolysis, their toxicity has been explained by
some mechanisms that differ from that of their catalytic-
ally active PLA2 counterparts. It has been suggested that
the C-terminal region of Lys49-PLA2s from Bothrops
venoms is critical for their biological activities [14, 29–33].
The nociceptive effect of Lys49-PLA2 has also been inves-
tigated, and we have previously shown that the C-terminal
region of the Lys49-PLA2 from Bothrops asper venom is
important for hyperalgesia, since the intraplantar injection
of a peptide corresponding to amino acids 115–119 in the
C-terminal region of the protein induces hyperalgesia in
rats. In contrast, a C-terminal peptide derived from the
same region of the Asp49-PLA2 did not show any noci-
ceptive effect [11].
It has been demonstrated that the C-terminal region
of the Lys-PLA2 region is also responsible for cytolytic,
edematogenic, and myotoxic activities of this PLA2
[31, 34, 35]. Furthermore, this C-terminal region is
also endowed with bactericidal activity, and a peptide
corresponding to residues 115–119 of the BthTx-I
reproduces the antimicrobial effect of the role Lys49-
PLA2 [36, 37]. Taken together these data indicate that
the C-terminal region may have an important role in
the biological effects of venom-derived Lys49-PLA2.
However, crystallographic and site-directed mutagen-
esis studies have suggested that additional residues,
other than those located at C-terminal, participate in
Lys49-PLA2 toxicity, and Lys20 is also critical for the
myotoxic activity of this molecule [29, 32].
Despite the importance of the C-terminal region for
the different biological activities of the Lys49-PLA2s, the
membrane damaging, myotoxic and bactericidal activities
have distinct structural determinants. This suggestion is
based on scanning alanine mutagenesis studies showing
that the structural determinants of the bactericidal activity
are more extensive and only partially overlap with the
Fig. 4 Effect of BthTx-I K122A (Lys122→ Ala) mutagenesis on rat pain threshold and paw volume. Decrease in a threshold response and b paw
volume were determined in rat hind paw before and 2, 4, 6 and 24 h after the intraplantar injection of PBS (control group) or R122A, or recombinant
BthTx-I. Sensitivity to pain was measured as the threshold response to pressure and expressed as g. The paw volume was obtained pletsmografically.
Each point represents the mean ± SEM of six animals. *Significantly different from mean values before venom injection (p < 0.05)
Fig. 5 Effect of H48Q (BthTx-I His48→Gln) mutagenesis on rat pain threshold and paw volume. Decrease in a threshold response and b paw volume
were determined in rat hind paw before and 2, 4, 6 and 24 h after the intraplantar injection of PBS (control group) or H48Q, or recombinant BthTx-I.
Sensitivity to pain was measured as the threshold response to pressure and expressed as g. The paw volume was obtained pletsmografically. Each point
represents the mean ± SEM of six animals. *Significantly different from mean values before venom injection (p < 0.05)
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structural determinants of the myotoxic and cytolytic
activities [14, 29]. However, the results obtained in the
present study indicate a degree of similarity in the struc-
tural determinants involved in the myotoxic, cytolytic,
hyperalgesic and edematogenic effects. This observation is
based on data showing that:
 The same residue responsible for the myotoxic
activity (R118) also contributes to the edematogenic
and hyperalgesic responses induced by BthTx-I [14].
 Residues 115 and 116, which are determinants for
the Ca2+-independent membrane damaging activity
of the BthTx-I, are also critical for the hyperalgesic
effect of this Lys-PLA2, but not for the edematogenic
response [12, 14, 29].
 The R122A, which contributes to both the myotoxic
and cytolytic activities of BthTX-I, is also important
for hyperalgesia and edema.
The results obtained in this study indicate that the
BthTx-I-induced hyperalgesia depends on the main bio-
logical activities of this Lys-PLA2, since elimination of
the myotoxic and cytolytic activities also abolished
hyperalgesia. In contrast, the edematogenic response is
less dependent on the cytolytic effects of BthTx-I, since
the elimination of myotoxicity interfered with this activ-
ity. These data also suggest that hyperalgesia and edema
caused by this Lys-PLA2s are not directly correlated.
Previous data from our group have demonstrated that
different mediators are involved in the genesis of hyper-
algesia and edema caused by Lys49 and Asp49-PLA2s
from Bothrops snake venoms, reinforcing the suggestion
that hyperalgesia and edema induced by BthTx-I are not
directly dependent [11].
The mechanisms that contribute to myotoxicity and to
hyperalgesia and edema of the Lys49-PLA2s are not yet
characterized. Preliminary data have demonstrated that
the R118 mutant, which is devoid of myotoxic activity, in-
duces decreased edematogenic activity, and a substantial
drop in the number of local neutrophils (Zambelli and
Cury, 2004, personal communication), confirming the im-
portance of myotoxicity to the inflammatory response
caused by this molecule. Despite the evidences indicating
a possible correlation between myotoxicity and inflamma-
tion, we should also consider that a reduction in myotoxi-
city abrogates hyperalgesia by a mechanism independent
of inflammation. The Lys49-PLA2 from B. asper induces a
ATP and K+ release from C2C12 myotubes in culture and
from mouse muscles [38]. It has been demonstrated that
these mediators can directly induce pain by activating pur-
inergic receptors or inducing membrane depolarization of
peripheral sensory nerves [38–40]. Therefore, a direct link
between myotoxicity and pain generation may exist.
The data showing that the residues 115 and 116 are
critical for hyperalgesia, but not for edema formation,
also adds evidence that nociception and edema are not
directly correlated, and may have distinct structural
determinants. Although there is no data available to
explain how these residues contribute exclusively for
hyperalgesia, these mutations are involved in the BthTx-I
cytolytic activity and a direct effect of cytotoxicity on
pain generation is a possibility. Further experiments are
necessary to investigate this hypothesis.
To further characterize the structural determinants in-
volved in BthTx-I-induced hyperalgesia, and to evaluate
whether a putative residual catalytic activity of the Lys49-
PLA2 could play a role in the hyperalgesia and the edema
induced by BthTx-I, we tested the H48Q mutant in our
experimental conditions. The hydrolytic mechanism of
Asp49-PLA2s involves the His48 in the catalytic site that
activates a conserved water molecule, thereby initiating
the nucleophilic attack on the sn-2 position of the
phospholipid substrate and the H48Q mutation abolishes
this activity [41, 42]. Here we observe that H48Q mutation
does not interfere with the hyperalgesic and edematogenic
effects induced by the BthTx-I, confirming that only the
C-terminal amino acids are relevant for the BthTx-I
pharmacological activities. It is important to highlight that
Fig 6 Characterization of allodynia induced by native and recombinant BthTx-I (a) and mutants BthTx-I (b). Decrease in tactile threshold was
evaluated by von Frey test, before and 2, 4, 6 and 24 h after the intraplantar injection of PBS (control group), native, recombinant BthTx-I (a) or
BthTx-I mutants (b). Sensitivity to pain was measured as the threshold response to tactile and expressed as g Log (mg × 10). Each point represents
the mean ± SEM of six animals. *Significantly different from mean values before venom injection (p < 0.05)
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the H48Q mutation does not alter the myotoxicity or the
membrane damaging effects of the BthTx-I [14].
The data presented here suggest that residues present in
the C-terminal region of the BthTx-I are important for
hyperalgesia and edema. Previous studies have demon-
strated that the synthetic peptide 115–129 was unable to
mimic some effects of the whole toxin, such as in vitro
and in vivo myotoxicity, and toxicity against epithelial
cells and erythrocytes [30, 37]. These findings indicate
that other residues present in the whole molecule or
the quaternary structure of Lys49-PLA2s are critical
for the for the biological activity of these molecules
[32, 43]. However, the absence of toxicity observed for
the synthetic peptide 115–129 do not exclude the partici-
pation of C-terminal residues in the pharmacological
effects evaluated.
Conclusions
In conclusion, the results obtained with the BthTx-I mu-
tants suggest, for the first time, that there are distinct resi-
dues responsible for the hyperalgesia and edema induced
by BthTx-I. In addition, we also showed that the cytolytic
activity is essential for the hyperalgesic effect but not for
edematogenic activity, reinforcing previous data showing
that edema and hyperalgesia can occur independently. A
better understanding about the structure-activity relation-
ship can open new avenues of investigation to identify the
target for PLA2-induced pain.
Abbreviations
ANOVA: analysis of variance; BthTx-I: bothropstoxin-I; cDNA: complementary
deoxyribonucleic acid; EDTA: ethylenediaminetetraacetic acid; H48Q: His48→
Gln; K115A: Lys115→ Ala; K116A: Lys116→ Ala; K122A: Lys122→ Ala;
MgSO4: magnesium sulfate; PLA2: phospholipase A2; PLA2-Lys49: phospholipase
A2 with a Lys at position 49; R118A: Arg118→ Ala; RT-PCR: reverse transcriptase
polymerase chain reaction; Tris–HCl: Tris hydrochloride
Acknowledgments
Thanks are to the Center for the Study of Venoms and Venomous Animals
(CEVAP) of UNESP for enabling the publication of this paper (Edital
Toxinologia CAPES no. 063/2010, Process no. 230.38.006285/2011-21, AUXPE
Toxinologia 1219/2011).
Funding
This work was supported by a grant from the State of São Paulo Research
Foundation (FAPESP, grant no. 2002/12906-0) and by Butantan Foundation,
São Paulo, Brazil.
Authors’ contributions
YC, RJW and VOZ conceived the project. VOZ, LC, VPG and YC designed and
performed the experiments and carried out data analysis. VOZ wrote the
manuscript with input from RJW. All authors read and approved the final
manuscript.
Competing interests




All animal tests were conducted in accordance with the guidelines of the
International Association for the Study of Pain [20]. The present study was
approved by the Institutional Animal Care Committee of the Butantan
Institute (CEUAIB, protocol number 118/2002).
Author details
1Butantan Institute, Special Laboratory for Pain and Signaling, Av. Vital Brazil,
1500, São Paulo, SP CEP 05503-900, Brazil. 2Department of Chemistry, School
of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo
(USP), Ribeirão Preto, SP, Brazil.
Received: 1 September 2016 Accepted: 1 February 2017
References
1. Dennis EA. Diversity of group types, regulation, and function of
phospholipase A2. J Biol Chem. 1994;269(18):13057–60.
2. Valentin E, Lambeau G. Increasing molecular diversity of secreted
phospholipases A2 and their receptors and binding proteins. Biochim
Biophys Acta. 2000;1488(1–2):59–70.
3. Harris LK, Franson RC. [1-14C] oleate-labeled autoclaved yeast: a
membranous substrate for measuring phospholipase A2 activity in vitro.
Anal Biochem. 1991;193(2):191–6.
4. Dunn RD, Broady KW. Snake inhibitors of phospholipase A2 enzymes.
Biochim Biophys Acta. 2001;1533(1):29–37.
5. Arni RK, Ward RJ. Phospholipase A2–a structural review. Toxicon. 1996;
34(8):827–41.
6. Gutiérrez JM, Lomonte B. Phospholipase A2 myotoxins from Bothrops snake
venoms. Toxicon. 1995;33(11):1405–24.
7. de Oliveira AH, Giglio JR, Andrião-Escarso SH, Ito AS, Ward RJ. A pH-induced
dissociation of the dimeric form of a lysine 49-phospholipase A2 abolishes
Ca2 + −independent membrane damaging activity. Biochemistry. 2001;
40(23):6912–20.
8. Ownby CL. Selistre de Araujo HS, White SP, Fletcher JE. Lysine 49
phospholipase A2 proteins. Toxicon. 1999;37(3):411–45.
9. Soares AM, Guerra-Sá R, Borja-Oliveira CR, Rodrigues VM, Rodrigues-Simioni
L, Rodrigues V, et al. Structural and functional characterization of BnSP-7, a
Lys49 myotoxic phospholipase A2 homologue from Bothrops neuwiedi
pauloensis venom. Arch Biochem Biophys. 2000;378(2):201–9.
10. Páramo L, Lomonte B, Pizarro-Cerdá J, Bengoechea JA, Gorvel JP, Moreno E.
Bactericidal activity of Lys49 and Asp49 myotoxic phospholipases A2 from
Bothrops asper snake venom–synthetic Lys49 myotoxin II-(115–129)- peptide
identifies its bactericidal region. Eur J Biochem. 1998;253(2):452–61.
11. Chacur M, Longo I, Picolo G, Gutiérrez JM, Lomonte B, Guerra JL, et al.
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from
Bothrops asper snake venom: pharmacological mediation and molecular
determinants. Toxicon. 2003;41(6):667–78.
12. Mamede CCN, de Sousa BB, Pereira DFC, Matias MS, de Queiroz MR, de
Morais NCG, et al. Comparative analysis of local effects caused by Bothrops
alternatus and Bothrops moojeni snake venoms: enzymatic contributions and
inflammatory modulations. Toxicon. 2016;117:37–45.
13. Teixeira CF, Landucci EC, Antunes E, Chacur M, Cury Y. Inflammatory effects
of snake venom myotoxic phospholipases A2. Toxicon. 2003;42(8):947–62.
14. Chioato L, De Oliveira AH, Ruller R, Sá JM, Ward RJ. Distinct sites for
myotoxic and membrane-damaging activities in the C-terminal region of a
Lys49-phospholipase A2. Biochem J. 2002;366(Pt 3):971–6.
15. Ruller R, Aragão EA, Chioato L, Ferreira TL, de Oliveira AH, Sà JM, et al. A
predominant role for hydrogen bonding in the stability of the homodimer
of bothropstoxin-I, a lysine 49-phospholipase A2. Biochimie. 2005;87
(11):993–1003.
16. Laemmli UK. Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature. 1970;227(5259):680–5.
17. Ward RJ, Monesi N, Arni RK, Larson RE, Paço-Larson ML. Sequence of a
cDNA encoding bothropstoxin I, a myotoxin from the venom of Bothrops
jararacussu. Gene. 1995;156(2):305–6.
18. Ward RJ, de Oliveira AH, Bortoleto RK, Rosa JC, Faça VM, Greene LJ.
Refolding and purification of Bothropstoxin-I, a Lys49-phospholipase A2
homologue, expressed as inclusion bodies in Escherichia coli. Protein Expr
Purif. 2001;21(1):134–40.
Zambelli et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2017) 23:7 Page 8 of 9
19. Nelson RM, Long GL. A general method of site-specific mutagenesis using a
modification of the Thermus aquaticus polymerase chain reaction. Anal
Biochem. 1989;180(1):147–51.
20. Zimmermann M. Ethical guidelines for investigations of experimental pain
in conscious animals. Pain. 1983;16(2):109–10.
21. Randallo LO, Selitto JJ. A method for measurement of analgesic activity on
inflamed tissue. Arch Int Pharmacodyn Ther. 1957;111(4):409–19.
22. Zambelli VO, Gross ER, Chen CH, Gutierrez VP, Cury Y, Mochly-Rosen D.
Aldehyde dehydrogenase-2 regulates nociception in rodent models of
acute inflammatory pain. Sci Transl Med. 2014;6(251):251ra118.
23. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative
assessment of tactile allodynia in the rat paw. J Neurosci Methods.
1994;53(1):55–63.
24. Milligan ED, Mehmert KK, Hinde JL, Harvey LO, Martin D, Tracey KJ, et al.
Thermal hyperalgesia and mechanical allodynia produced by intrathecal
administration of the human immunodeficiency virus-1 (HIV-1) envelope
glycoprotein, gp120. Brain Res. 2000;861(1):105–16.
25. Milligan ED, Twining C, Chacur M, Biedenkapp J, O’Connor K, Poole S, et al.
Spinal glia and proinflammatory cytokines mediate mirror-image
neuropathic pain in rats. J Neurosci. 2003;23(3):1026–40.
26. Van Arman CG, Nuss GW. Plasma bradykininogen levels in adjuvant arthritis
and carrageenan inflammation. J Pathol. 1969;99(3):245–50.
27. Melaré R, Floriano RS, Gracia M, Rodrigues-Simioni L, da Cruz-Höfling MA,
Rocha T. Ultrastructural aspects of mouse nerve-muscle preparation
exposed to Bothrops jararacussu and Bothrops bilineatus venoms and their
toxins BthTX-I and Bbil-TX: Unknown myotoxic effects. Microsc Res Tech.
2016;79(11):1082–9.
28. Landucci EC, Castro RC, Pereira MF, Cintra AC, Giglio JR, Marangoni S, et al.
Mast cell degranulation induced by two phospholipase A2 homologues:
dissociation between enzymatic and biological activities. Eur J Pharmacol.
1998;343(2–3):257–63.
29. Chioato L, Aragão EA, Lopes Ferreira T, Ivo de Medeiros A. Mapping of the
structural determinants of artificial and biological membrane damaging
activities of a Lys49 phospholipase A2 by scanning alanine mutagenesis.
Biochim Biophys Acta. 2007;176(5):1247–57.
30. Lomonte B, Angulo Y, Santamaría C. Comparative study of synthetic
peptides corresponding to region 115–129 in Lys49 myotoxic
phospholipases A2 from snake venoms. Toxicon. 2003;42(3):307–12.
31. Núñez CE, Angulo Y, Lomonte B. Identification of the myotoxic site of
the Lys49 phospholipase A(2) from Agkistrodon piscivorus piscivorus
snake venom: synthetic C-terminal peptides from Lys49, but not from
Asp49 myotoxins, exert membrane-damaging activities. Toxicon. 2001;
39(10):1587–94.
32. dos Santos JI, Soares AM, Fontes MRM. Comparative structural studies on
Lys49-phospholipases A(2) from Bothrops genus reveal their myotoxic site.
J Struct Biol. 2009;167(2):106–16.
33. Lomonte B, Angulo Y, Moreno E. Synthetic peptides derived from the
C-terminal region of Lys49 phospholipase A2 homologues from viperidae
snake venoms: biomimetic activities and potential applications. Curr Pharm
Des. 2010;16(28):3224–30.
34. Lomonte B, Moreno E, Tarkowski A, Hanson LA, Maccarana M. Neutralizing
interaction between heparins and myotoxin II, a lysine 49 phospholipase A2
from Bothrops asper snake venom. Identification of a heparin-binding and
cytolytic toxin region by the use of synthetic peptides and molecular
modeling. J Biol Chem. 1994;269(47):29867–73.
35. Calderón L, Lomonte B. Immunochemical characterization and role
in toxic activities of region 115–129 of myotoxin II, a Lys49
phospholipase A2 from Bothrops asper snake venom. Arch Biochem
Biophys. 1998;358:343–50.
36. Aragão EA, Chioato L, Ward RJ. Permeabilization of E. coli K12 inner and
outer membranes by bothropstoxin-I, A LYS49 phospholipase A2 from
Bothrops jararacussu. Toxicon. 2008;51(4):538–46.
37. Santos-Filho NA, Lorenzon EN, Ramos MA, Santos CT, Piccoli JP, Bauab TM,
et al. Synthesis and characterization of an antibacterial and non-toxic
dimeric peptide derived from the C-terminal region of Bothropstoxin-I.
Toxicon. 2015;103:160–8.
38. Cintra-Francischinelli M, Caccin P, Chiavegato A, Pizzo P, Carmignoto G,
Angulo Y, et al. Bothrops snake myotoxins induce a large efflux of ATP and
potassium with spreading of cell damage and pain. Proc Natl Acad Sci.
2010;107(32):14140–5.
39. Burnstock G. Purines and sensory nerves. Handb Exp Pharmacol. 2009;
194:333–92.
40. Lim RKS. Neuropharmacology of pain and analgesia. Pharmacology of Pain:
Proceedings of the First International Pharmacological edited by Lim RKS,
Armstrong DEG. PardoPharmacol Pain 9. 2013. p. 169–217.
41. Verheij HM, Volwerk JJ, Jansen EH, Puyk WC, Dijkstra BW, Drenth J, et al.
Methylation of histidine-48 in pancreatic phospholipase A2. Role of histidine
and calcium ion in the catalytic mechanism. Biochemistry. 1980;19(4):743–50.
42. Scott DL, Otwinowski Z, Gelb MH, Sigler PB. Crystal structure of bee-venom
phospholipase A2 in a complex with a transition-state analogue. Science.
1990;250(4987):1563–6.
43. Lomonte B, Rangel J. Snake venom Lys49 myotoxins: From phospholipases
A(2) to non-enzymatic membrane disruptors. Toxicon. 2012;60(4):520–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zambelli et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2017) 23:7 Page 9 of 9
